Lawsuit against Eli Lilly over Zyprexa dismissed
NEW YORK U.S. District Judge Jack Weinstein has dismissed a lawsuit that claimed that Eli Lilly defrauded shareholders by hiding information about the health risks and marketing of its schizophrenia and bipolar disorder drug Zyprexa, according to Bloomberg.
Weinstein said that the claim was filed too late because, federal law requires that shareholder lawsuits be brought within two years of when investigators should know they have a claim.
The investors, who bought Lilly stock between August 2002 and December 2006, claimed the drugmaker hid information that Zyprexa can cause diabetes and other diseases and marketed the drug for uses not approved by the Food and Drug Administration. They said they lost money when the alleged fraud became public and Lilly shares fell.
FDA approves first U.S. drug for IBS-C
WASHINGTON Takeda and Sucampo Pharmaceuticals’ Amitiza, indicated for treatment of irritable bowel syndrome with constipation, was approved by the Food and Drug Administration for women over the age of 18, according to published reports.
IBS, an ailment characterized by cramping, abdominal pain, bloating, constipation and diarrhea, affects twice as many women as men, the FDA said. The reason for Amitiza’s approval for women only, however, was based on a lack of proof that the drug was effective for men.
“For some people IBS can be quite disabling, making it difficult for them to fully participate in everyday activities,” said Julie Beitz of the FDA’s Center for Drug Evaluation and Research. “This drug represents an important step in helping to provide medical relief from their symptoms.”
Amitiza (lubiprostone) is already approved for the treatment of chronic idiopathic constipation, though at a much higher dosage than for treatment of IBS-C.
CDC says more than 25% of children not receiving recommended vaccinations
WASHINGTON According to the Centers for Disease Control and Prevention, more than a quarter of children in the U.S. are not meeting childhood vaccinations in accordance with government recommendation, according to Reuters. The study was of children between the ages of 18 months and 3-years-old.
The report went beyond studying if children were getting the recommended number of doses of various vaccines by, examining whether the children were getting them at the right time.
CDC researchers found that 28 percent did not meet vaccination recommendations. The results were based on a 2005 government survey involving 17,563 U.S. children in that age group.
Missed doses accounted for about two-thirds of those not in compliance. The rest of the children got them at the wrong age or too soon after a previous dose to be considered completely effective. Using the usual method of examining only whether children got the right number of doses, 81 percent of the children met government recommendations, according to the CDC.
The CDC recommends a number of vaccines to protect children against diseases like measles, polio, mumps, chicken pox and several others. Some require multiple doses.